Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics.
This study evaluated the coronary dopamine receptors by using the dopamine D1 receptor agonist fenoldopam, dopamine D2 receptor agonist propylbutyldopamine, and their selective antagonists SCH23390 and domperidone. Left circumflex coronary flow (CF), coronary perfusion pressure at constant flow, left ventricular hemodynamics, and total peripheral vascular resistance (TPR) were measured in pentobarbital-anesthetized dogs at constant arterial pressures. At doses of 200, 500 and 5000 nM, both fenoldopam and propylbutyldopamine induced dose-related inotropic effects, as evidenced by maximal dp/dt and cardiac output, an increase in CF, decrease in coronary vascular resistance and a decrease in TPR. Fenoldopam was more potent in its cardiac and coronary effects while propylbutyldopamine was more potent peripherally. On the basis of dosage used, the positive inotropic effects of fenoldopam and propylbutyldopamine were much weaker than dopamine. After beta-receptor blockade, the inotropic and coronary effects of fenoldopam and propylbutyldopamine were extremely attenuated. Domperidone could largely antagonize the propylbutyldopamine-induced inotropic and coronary effects while SCH23390 showed no significant effect. In addition, under our experimental conditions, the fenoldopam- and propylbutyldopamine-induced decreases in TPR were markedly reduced by SCH23390 and domperidone, respectively. The results indicate that the coronary effects of fenoldopam and propylbutyldopamine result not from a primary coronary vasodilating action, but from vasodilation secondary to positive inotropic effects. Both dopamine D1 and dopamine D2 receptors are involved in the peripheral vascular hemodynamics.
Zhao
R R
RR
Department of Physiology, University of South Carolina, Columbia 29208.
Fennell
W H
WH
Abel
F L
FL
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology; D003326:Coronary Circulation / Q000187:drug effects*; D004285:Dogs; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects*; D014655:Vascular Resistance / Q000187:drug effects
D001552:Benzazepines; D002317:Cardiovascular Agents; D015259:Dopamine Agents; D011954:Receptors, Dopamine; D004294:Domperidone; C016080:N-n-propyl-N-n-butyl-beta-dopamine; D004298:Dopamine